PricewaterhouseCoopers

graphic image of China flags overlapping with US flags

China's rapid rise creates 'heightened risks' for pharma: PwC

Analysts warned the evolution of Chinese biotech is creating “heightened risks related to IP security, regulatory compliance and strategic alignment.”

Nick Paul Taylor Jun 18, 2025 5:00am

Mergers and acquisitions deals consolidation

PwC sees pharma-biotech deals 'to be extremely active in 2020'

Jan 24, 2020 10:30am

PwC to Biopharma: Use tech to address surge in data integrity violations

Apr 4, 2016 4:34am